<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253525</url>
  </required_header>
  <id_info>
    <org_study_id>14204</org_study_id>
    <secondary_id>CP12-1026</secondary_id>
    <secondary_id>I4T-IE-JVBW</secondary_id>
    <nct_id>NCT01253525</nct_id>
  </id_info>
  <brief_title>Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas</brief_title>
  <official_title>A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in
      combination with paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1</measure>
    <time_frame>Cycle 1 of 28-day cycle</time_frame>
    <description>DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia &gt;5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc&gt;500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay &gt;1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay &gt;2 weeks between Cy 1 and Cy 2 due to persistent tox.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to 47 weeks post baseline</time_frame>
    <description>The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 47 weeks post baseline</time_frame>
    <description>The number of participants who experienced SAEs that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1</measure>
    <time_frame>Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Cmax after a single dose of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)</measure>
    <time_frame>Cycle 1 through Cycle 5 (28-day cycles)</time_frame>
    <description>The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1</measure>
    <time_frame>Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Half-Life (t1/2) for Cycle 1</measure>
    <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Clearance (CL) or Cycle 1</measure>
    <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] after a single dose of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1</measure>
    <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Vss [distribution of ramucirumab (IMC-1121B) in the body at steady state] after a single dose of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2</measure>
    <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Cmax after multiple doses of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2</measure>
    <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Half-Life (t1/2) for Cycle 2</measure>
    <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Terminal t1/2 [the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%] after multiple doses of ramucirumab(IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Clearance (CL) for Cycle 2</measure>
    <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] at steady state after multiple doses of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2</measure>
    <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
    <description>Vss [distribution of ramucirumab (IMC-1121B) in in the body at steady state] is not calculated for multiple doses of ramucirumab (IMC-1121B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3</measure>
    <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3</measure>
    <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Half-Life (t 1/2) for Cycle 3</measure>
    <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Clearance (CL) for Cycle 3</measure>
    <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3</measure>
    <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4</measure>
    <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4</measure>
    <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Half-Life (t 1/2) for Cycle 4</measure>
    <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Clearance (CL) for Cycle 4</measure>
    <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4</measure>
    <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
    <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ramucirumab (IMC-1121B ) and Pacitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment cycle is 4 weeks (28 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ramucirumab (IMC-1121B )</intervention_name>
    <description>8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle</description>
    <arm_group_label>Ramucirumab (IMC-1121B ) and Pacitaxel</arm_group_label>
    <other_name>LY3009806</other_name>
    <other_name>IMC-1121B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle</description>
    <arm_group_label>Ramucirumab (IMC-1121B ) and Pacitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histopathologically or cytologically confirmed diagnosis of gastric or
             gastroesophageal junction (GEJ) adenocarcinoma

          -  Has an advanced or metastatic solid gastric adenocarcinoma that has failed standard
             therapy

          -  Has resolution of all clinically significant toxic effects of prior therapy, surgery,
             treatment with an investigational agent or device, treatment monoclonal antibody or
             small molecule, and radiotherapy or chemotherapy.

          -  Has adequate organ function

          -  Eligible participants of reproductive potential (both sexes) agree to use adequate
             contraceptive methods (hormonal or barrier methods) during the study period and for 12
             weeks after the last dose of study medication

        Exclusion Criteria:

          -  Has undergone major surgery within 28 days prior to the study, or subcutaneous venous
             access device placement within 7 days prior to the study registration date

          -  Has elective or planned surgery to be conducted during the trial

          -  Has had treatment with an investigational agent or device, an antineoplastic small
             molecule, or antineoplastic radiotherapy or chemotherapy

          -  Was previously treated with a chemotherapy regimen containing nitrosoureas or
             mitomycin C

          -  Has had treatment with an antineoplastic monoclonal antibody within 8 weeks prior to
             the study registration date

          -  Has a history of deep vein thrombosis, pulmonary embolism, or any other significant
             thromboembolism prior to the study registration date

          -  Has experienced any arterial thrombotic event, including myocardial infarction,
             cerebrovascular accident, or transient ischemic attack, within 6 months prior to the
             study date

          -  Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin
             or similar agents. (Participants receiving prophylactic, low-dose anticoagulation
             therapy are eligible provided that the coagulation parameters International Normalized
             Ratio (INR) ≤ 1.5, prothrombin time (PT) and partial thromboplastin time (PTT) or - Is
             receiving chronic therapy with nonsteroidal anti-inflammatory agents [Aspirin use at
             doses up to 325 milligrams/day (mg/day) is permitted]

          -  Has significant bleeding disorders, vasculitis, history of postoperative bleeding
             complications, hemoptysis or had a significant bleeding episode from the
             gastrointestinal (GI) tract within 3 months prior to the study date

          -  Has a history of GI perforation and/or fistulae within 6 months prior to the study
             date

          -  Has symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or
             poorly controlled cardiac arrhythmia

          -  Has uncontrolled arterial hypertension despite standard medical management.

          -  Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days
             prior to the study date

          -  Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive
             intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea

          -  Has a serious illness or medical condition(s)

          -  Is pregnant or lactating

          -  Has received treatment with another investigational drug or participation in another
             interventional clinical trial within 28 days prior to the study date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>589-5811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were considered completed if they either completed Cycle 1 of study drug or discontinued study drug due to a dose limiting toxicity (DLT) during Cycle 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ramucirumab + Paclitaxel</title>
          <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Any Quantity of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Ramucirumab + Paclitaxel</title>
          <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1</title>
        <description>DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia &gt;5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc&gt;500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay &gt;1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay &gt;2 weeks between Cy 1 and Cy 2 due to persistent tox.</description>
        <time_frame>Cycle 1 of 28-day cycle</time_frame>
        <population>All enrolled participants who complete the first cycle of study drug or discontinued study drug due to a DLT during Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1</title>
          <description>DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia &gt;5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc&gt;500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay &gt;1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay &gt;2 weeks between Cy 1 and Cy 2 due to persistent tox.</description>
          <population>All enrolled participants who complete the first cycle of study drug or discontinued study drug due to a DLT during Cycle 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
        <time_frame>Up to 47 weeks post baseline</time_frame>
        <population>All enrolled participants who received any quantity of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
          <population>All enrolled participants who received any quantity of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RAM-Related AEs Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAC-Related AEs Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAM-Related AEs Any Grade ≥3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAC-Related AEs Any Grade ≥3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAM-Related AEs Resulting in Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAC-Related AEs Resulting in Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>The number of participants who experienced SAEs that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
        <time_frame>Up to 47 weeks post baseline</time_frame>
        <population>All enrolled participants who received any quantity of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>The number of participants who experienced SAEs that were considered to be related to ramucirumab [RAM (IMC-1121B)] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module.</description>
          <population>All enrolled participants who received any quantity of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RAM-Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAC-Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1</title>
        <description>Cmax after a single dose of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable Cmax values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1</title>
          <description>Cmax after a single dose of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable Cmax values.</population>
          <units>micrograms/milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)</title>
        <description>The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.</description>
        <time_frame>Cycle 1 through Cycle 5 (28-day cycles)</time_frame>
        <population>All enrolled participants who received at least 1 dose of study drug and were analyzed for anti-ramucirumab (IMC-1121B) antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)</title>
          <description>The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies.</description>
          <population>All enrolled participants who received at least 1 dose of study drug and were analyzed for anti-ramucirumab (IMC-1121B) antibodies.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1</title>
        <description>AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable AUC0-∞ values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1</title>
          <description>AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable AUC0-∞ values.</population>
          <units>micrograms*hour/milliliter (µg*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34100">Standard deviation cannot be calculated with results from 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Half-Life (t1/2) for Cycle 1</title>
        <description>Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable t1/2 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Half-Life (t1/2) for Cycle 1</title>
          <description>Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable t1/2 values.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" lower_limit="138" upper_limit="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Clearance (CL) or Cycle 1</title>
        <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] after a single dose of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable CL values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Clearance (CL) or Cycle 1</title>
          <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] after a single dose of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable CL values.</population>
          <units>liters/hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0166">Standard deviation cannot be calculated with results from 1 participant analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1</title>
        <description>Vss [distribution of ramucirumab (IMC-1121B) in the body at steady state] after a single dose of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable Vss values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1</title>
          <description>Vss [distribution of ramucirumab (IMC-1121B) in the body at steady state] after a single dose of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable Vss values.</population>
          <units>liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27">Standard deviation cannot be calculated with results from 1 participant analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2</title>
        <description>Cmax after multiple doses of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable Cmax values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2</title>
          <description>Cmax after multiple doses of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable Cmax values.</population>
          <units>micrograms/milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2</title>
        <description>AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable AUC 0-τ values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2</title>
          <description>AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable AUC 0-τ values.</population>
          <units>micrograms*hour/milliliter (µg*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41900" spread="951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Half-Life (t1/2) for Cycle 2</title>
        <description>Terminal t1/2 [the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%] after multiple doses of ramucirumab(IMC-1121B).</description>
        <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable t1/2 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Half-Life (t1/2) for Cycle 2</title>
          <description>Terminal t1/2 [the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%] after multiple doses of ramucirumab(IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable t1/2 values.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="218" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Clearance (CL) for Cycle 2</title>
        <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] at steady state after multiple doses of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>All enrolled participants who received any quantity of study drug and had evaluable CL values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Clearance (CL) for Cycle 2</title>
          <description>CL [the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time] at steady state after multiple doses of ramucirumab (IMC-1121B).</description>
          <population>All enrolled participants who received any quantity of study drug and had evaluable CL values.</population>
          <units>liters/hour (L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0136" spread="0.000342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2</title>
        <description>Vss [distribution of ramucirumab (IMC-1121B) in in the body at steady state] is not calculated for multiple doses of ramucirumab (IMC-1121B).</description>
        <time_frame>Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2</title>
          <description>Vss [distribution of ramucirumab (IMC-1121B) in in the body at steady state] is not calculated for multiple doses of ramucirumab (IMC-1121B).</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3</title>
        <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.</description>
        <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3</title>
          <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3</title>
        <description>Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.</description>
        <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3</title>
          <description>Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Half-Life (t 1/2) for Cycle 3</title>
        <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.</description>
        <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Half-Life (t 1/2) for Cycle 3</title>
          <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Clearance (CL) for Cycle 3</title>
        <description>Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.</description>
        <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Clearance (CL) for Cycle 3</title>
          <description>Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3</title>
        <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.</description>
        <time_frame>Cycle 3: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3</title>
          <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4</title>
        <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.</description>
        <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4</title>
          <description>Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4</title>
        <description>Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
        <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4</title>
          <description>Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Half-Life (t 1/2) for Cycle 4</title>
        <description>Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
        <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Half-Life (t 1/2) for Cycle 4</title>
          <description>Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Clearance (CL) for Cycle 4</title>
        <description>Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
        <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Clearance (CL) for Cycle 4</title>
          <description>Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4</title>
        <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
        <time_frame>Cycle 4: Pre-infusion, Day 1 of 28-day cycle</time_frame>
        <population>Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramucirumab + Paclitaxel</title>
            <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4</title>
          <description>Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4.</description>
          <population>Zero participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ramucirumab + Paclitaxel</title>
          <description>Ramucirumab (IMC-1121B): 8 milligrams/kilogram (mg/kg) administered intravenously on Days 1 and 15 of each 28-day cycle.
Paclitaxel: 80 milligrams/square meter (mg/m2) administered intravenously on Days 1, 8, and 15 of each 28-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphangiosis carcinomatosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Cycle 3 and beyond pharmacokinetic sampling was collected per the protocol-defined limited sampling schedule.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

